证券代码：002675 证券简称：东诚药业 公告编号：2024-058 烟台东诚药业集团股份有限公司 关于控股股东部分股权质押、展期及补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 截至公告披露日，控股股东东益生物及其一致行动人所持质押股份情况如下： 股东名 称 持股数量 （股） 持股比 例 累计质押 数量（股） 占其所 持股份 比例 占公司 总股本 比例 已质押股份情况 未质押股份情况 已质押股 份限售和 冻结数量 （股） 占已质 押股份 比例 未质押股 份限售和 冻结数量 （股） 占未质 押股份 比例 烟台东 益生物 工程有 限公司 124,888,049 15.15% 34,025,000 27.24% 4.13% 0 0 0 0 由守谊 103,305,678 12.53% 52,548,000 50.87% 6.37% 41,518,000 79.01% 35,961,258 70.85% 厦门鲁 鼎志诚 股权投 资管理 合伙企 业（有 限合 伙） 3,056,768 0.37% 0 0 0 0 0 0 0 合计 231,250,49 ...

Financial Performance - Revenue for the reporting period was RMB 1.42 billion, a decrease of 20.41% compared to the same period last year[10] - Net profit attributable to shareholders of the listed company was RMB 111.79 million, a decrease of 39.35% year-on-year[10] - Net cash flow from operating activities was negative RMB 17.79 million, a significant decrease of 245.45% compared to the same period last year[10] - Basic earnings per share (EPS) was RMB 0.1356, down 39.33% year-on-year[10] - Total assets increased by 7.26% to RMB 8.67 billion compared to the end of the previous year[10] - Shareholders' equity decreased by 7.02% to RMB 4.44 billion compared to the end of the previous year[10] - The weighted average return on equity (ROE) was 2.33%, down 1.48 percentage points from the same period last year[10] - Revenue for the first half of 2024 was 1.421 billion yuan, a year-on-year decrease of 20.41%[15] - Net profit attributable to shareholders was 112 million yuan, a year-on-year decrease of 39.35%[15] - Revenue for the first half of 2024 decreased to 651,973,024.64 RMB, a significant drop from 926,651,055.45 RMB in the same period of 2023[112] - Net profit for the first half of 2024 was 68,909,543.50 RMB, compared to 160,804,051.67 RMB in the first half of 2023[112] - Operating cash flow for the first half of 2024 was negative at -17,786,859.20 RMB, a sharp decline from 12,228,463.70 RMB in the same period of 2023[114] - Sales revenue from goods and services in the first half of 2024 was 1,351,467,618.40 RMB, down from 1,877,162,768.94 RMB in the first half of 2023[114] - R&D expenses for the first half of 2024 were 20,127,405.08 RMB, a decrease from 26,333,874.80 RMB in the same period of 2023[112] - Interest income for the first half of 2024 was 7,662,506.26 RMB, slightly lower than 8,214,946.61 RMB in the first half of 2023[112] - Tax refunds received in the first half of 2024 were 49,417,487.10 RMB, down from 90,094,193.62 RMB in the same period of 2023[114] - Total comprehensive income for the first half of 2024 was 68,909,543.50 RMB, compared to 160,804,051.67 RMB in the first half of 2023[113] - Operating profit for the first half of 2024 was 82,255,458.94 RMB, a significant decrease from 182,749,108.33 RMB in the same period of 2023[112] - Investment losses for the first half of 2024 were -11,418,356.07 RMB, compared to a gain of 33,397,972.72 RMB in the first half of 2023[112] - Investment activities generated a net cash outflow of -481,241,778.83 yuan, compared to -247,378,033.30 yuan in the same period last year[115] - Financing activities generated a net cash inflow of 732,078,839.85 yuan, a significant increase from 109,794,678.94 yuan in the same period last year[115] - Cash and cash equivalents increased by 239,940,949.57 yuan, compared to a decrease of -123,558,257.08 yuan in the same period last year[115] - Sales revenue from goods and services was 556,657,607.02 yuan, a decrease from 934,866,051.98 yuan in the same period last year[115] - Investment income received was 4,025,196.95 yuan, a sharp decline from 50,893,205.53 yuan in the same period last year[115] - The company received 687,988,680.00 yuan from absorbing investments, a significant increase from 51,500,000.00 yuan in the same period last year[115] - The company repaid 474,119,112.54 yuan in debt, compared to 217,000,012.10 yuan in the same period last year[115] - The company's cash and cash equivalents at the end of the period were 847,679,131.19 yuan, compared to 803,292,557.04 yuan in the same period last year[115] - The company's total owner's equity at the end of the period was 5,395,623,912.68 yuan[117] - The company's net cash outflow from investment activities was -90,588,059.40 yuan, compared to a net inflow of 32,107,435.00 yuan in the same period last year[116] - The company's comprehensive income for the first half of 2024 was RMB 104.98 million, with a total comprehensive income of RMB 113.12 million[118] - The company's total equity at the end of the period was RMB 5.42 billion, an increase of RMB 149.27 million compared to the beginning of the period[121] - The company's net profit attributable to shareholders was RMB 181.80 million, a decrease of RMB 2.51 million compared to the same period last year[121] - The company's capital reserve increased by RMB 40.10 million during the period, reaching RMB 2.44 billion at the end of the period[122] - The company's undistributed profit at the end of the period was RMB 1.36 billion, an increase of RMB 560.62 million compared to the beginning of the period[121] - The company's total assets at the end of the period were RMB 8.25 billion, with total liabilities of RMB 2.84 billion[118] - The company's operating income for the first half of 2024 was RMB 2.34 billion, a decrease of RMB 337.31 million compared to the same period last year[118] - The company's minority shareholders' equity at the end of the period was RMB 584.74 million, an increase of RMB 51.07 million compared to the beginning of the period[122] - The company's total comprehensive income for the first half of 2024 was RMB 113.12 million, with a net profit attributable to shareholders of RMB 104.98 million[118] - The company's total equity at the end of the period was RMB 5.42 billion, with a total comprehensive income of RMB 113.12 million for the first half of 2024[121] Business Segments and Products - The company's products include heparin, low molecular weight heparin, chondroitin sulfate, and chondroitin sulfate sodium[4] - The company's subsidiaries are involved in nuclear medicine and biotechnology, such as Dongcheng Nuclear Medicine and Yantai Mindo[4] - The company's products are subject to GMP standards and NMPA regulations[4] - Nuclear medicine business revenue was 499 million yuan, a year-on-year decrease of 0.58%, with key product 18F-FDG revenue at 195 million yuan, down 4.30%[15] - API business revenue was 657 million yuan, a year-on-year decrease of 31.03%, with heparin API revenue at 483 million yuan, down 39.02%[15] - Formulation business revenue was 179 million yuan, a year-on-year decrease of 32.01%, with key product hydrocortisone sodium succinate injection revenue at 57.16 million yuan, down 22.38%[15] - The company received approval for Technetium [⁹⁹ᵐTc] Tektrotyd Injection, enhancing its product line and market competitiveness[16] - Mido Biotech has assisted in obtaining clinical trial approvals for over 20 nuclear medicine products and provides comprehensive CRO and CDMO services[17] - The company operates a global sales network across 40+ countries and regions, specializing in heparin API and chondroitin sulfate[18] - Heparin sodium API can be directly used to produce ordinary heparin preparations or low molecular weight heparin sodium API, which is widely used in clinical anticoagulation therapy[19] - Chondroitin sulfate is divided into pharmaceutical-grade and food-grade, with pharmaceutical-grade used for treating osteoarthritis, hyperlipidemia, and other diseases, while food-grade is used in health foods and beverages[19] - The company's nuclear medicine products adopt a production model based on sales orders, with long half-life products combining inventory and market conditions, while short half-life products use customized production[20] - The company's API products are sold through a mixed model of direct sales and distributor sales, with a sales network covering nearly 40 countries and regions[21] - The company's preparation business adopts a marketing model combining centralized procurement participation and agent promotion, with a focus on academic promotion and brand awareness[22] - The company's performance is driven by national policies promoting nuclear medicine development, including inclusion in the national medical insurance catalog and large medical equipment configuration plans[23] - The company has established a high-tech barrier nuclear medicine ecosystem network, forming a complete industrial chain from raw material supply to sales, with core competitiveness in product layout, production network layout, and innovative R&D[27] - The company has 30 operational nuclear medicine production centers, covering 93.5% of the domestic population's nuclear medicine needs, with 8 additional centers under construction[29] - The company's R&D platform, Yantai Lannacheng, focuses on radioactive diagnostic and therapeutic drugs, with multiple products in clinical trials, including 18F-Sirituximab in Phase III and 177Lu-LNC1004 in Phase I in China and Singapore[26] - The company has a diversified product line in nuclear medicine, covering diagnosis and treatment for cancer, neurodegenerative diseases, and cardiovascular diseases, with products like 18F-FDG, 99mTc-labeled drugs, and 131I-sodium iodide oral solution[28] - The company has a vertical integration advantage in the pharmaceutical industry, from raw materials to finished products, enhancing cost efficiency and market competitiveness[30] - The company is a global leader in heparin API production, with certifications from FDA, EDQM, and PMDA, and exports to over 40 countries[31] - The company has established a strong brand in the anticoagulant market, with a diverse product portfolio including nadroparin calcium and enoxaparin sodium injections[33] - The company has been recognized as one of the top 100 innovative enterprises in Shandong and ranked 47th in the 2023 China Chemical Pharmaceutical Enterprises Top 100 by MiNet[34] - The company operates in three main business segments: API (Active Pharmaceutical Ingredient), formulations, and nuclear medicine, with a global sales network spanning over 40 countries and regions[131] - The API segment is a leading global supplier of heparin API and chondroitin sulfate (both pharmaceutical and dietary supplement grades)[131] - The formulations segment includes a production capacity of 30 million freeze-dried powder injections annually, covering therapeutic areas such as anticoagulation, cardiovascular, oncology, urology, orthopedics, and anti-infectives[131] - The nuclear medicine segment focuses on building a full industry chain from diagnostic to therapeutic nuclear drugs, emphasizing integrated diagnosis and treatment and precision medicine[131] Subsidiaries and Investments - The company's subsidiaries include Dongcheng Northern, Dongcheng Ocean, Dongyuan Bio, Dongcheng Hong Kong, Yunkang Pharmaceutical, and Andike[4] - The company's subsidiaries operate in various regions, including Hong Kong, Nanjing, and Yantai[4] - The company's investment in Zhongtai Biological Products Co., Ltd. (70% equity) generated a net profit of 14,178,900 yuan in the reporting period[45] - The company invested RMB 20,000,000 in Qikang Yuan Medical Technology (Changzhou) Co., Ltd., acquiring a 50% stake[51] - The subsidiary Chengdu Yunke Pharmaceutical Co., Ltd. reported a net profit of RMB 57.04 million, with total assets of RMB 813.58 million and revenue of RMB 145.88 million[57] - Shanghai Xinke Pharmaceutical Co., Ltd. achieved a net profit of RMB 21.66 million, with total assets of RMB 155.59 million and revenue of RMB 103.01 million[57] - Nanjing Jiangyuan Andikezheng, another subsidiary, recorded a net profit of RMB 46.15 million, with total assets of RMB 1.59 billion and revenue of RMB 169.23 million[57] - Yantai Dongcheng Northern Pharmaceutical Co., Ltd. reported a net profit of RMB 10.85 million, with total assets of RMB 488.21 million and revenue of RMB 146.28 million[58] - Sino Siam Biotechnique Co., Ltd. achieved a net profit of RMB 14.18 million, with total assets of RMB 198.50 million and revenue of RMB 48.19 million[58] - Yantai Lannacheng Biotechnology Co., Ltd. reported a net loss of RMB 46.18 million, with total assets of RMB 416.08 million and no revenue[58] - Aprinoia Therapeutics Inc., a joint venture, recorded a net loss of RMB 61.96 million, with total assets of RMB 29.84 million and revenue of RMB 3.56 million[58] - The company's subsidiary YANTAI LNC BIOTECHNOLOGY SINGAPORE PTE.LTD. received FDA approval for clinical trials of 68 Ga-LNC1007 injection[87] - The company's subsidiary Lanacheng acquired the rights to the lung cancer imaging diagnostic nuclear medicine product for RMB 63 million[87] - The company's subsidiary Yitai Pharmaceutical acquired the rights to the liver function testing diagnostic nuclear medicine product for RMB 85 million[87] - The company's subsidiary Yantai Mido raised RMB 380 million through a capital increase from 7 investors[88] - The company's wholly-owned subsidiary subscribed to USD 4 million in convertible bonds of XING2DIAGNOSTICS, INC, accounting for 61.54% of the issuance[88] - The company's subsidiary LNC PHARMA PTE. LTD. received clinical trial authorization for 68 Ga-LNC1007 injection in Singapore[88] - The company's subsidiary Lanacheng raised RMB 300 million through a capital increase from 9 investors[88] - The company's subsidiary Lanacheng received clinical trial approval for 177 Lu-LNC1008 injection from the NMPA[88] - The company's subsidiary LNC PHARMA PTE. LTD. received FDA approval for clinical trials of 18 F-LNC1007 injection in Australia[88] - The new Hefei nuclear medicine production center of the wholly-owned subsidiary Andike has been put into operation, expanding the company's production capacity[89] - The subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 177 Lu-LNC1011 injection[89] - The wholly-owned subsidiary Andike obtained the NMPA approval for the production and sales of Technetium [99m Tc] Tetrofosmin Injection[89] - The holding subsidiary Yantai Lannacheng received NMPA approval for the clinical trial of 177 Lu-LNC1011 injection[89] Risks and Challenges - The company faces risks including raw material procurement, product quality, sales price fluctuations, production safety, and talent shortages[1] - The company faces risks from raw material price fluctuations, particularly due to the impact of African swine fever on heparin crude prices[60] - Increased depreciation from high fixed asset investments may lead to a decline in performance, especially during the initial phase of new projects[60] - The company is exposed to environmental and safety risks, with potential increases in compliance costs due to stricter regulations[60] - The company's future development statements are considered planning items and do not constitute substantive commitments to investors[1] Environmental and Safety Compliance - The company's wastewater treatment facilities use a combination of hydrolysis acidification, anaerobic, and aerobic processes, ensuring stable emission concentrations with online monitoring equipment installed at discharge points[67] - The company's exhaust gas treatment facilities primarily use spray absorption and activated carbon methods to pre-treat volatile organic compounds, ensuring emissions meet national and regional standards[67] - The company's actual environmental protection tax payment for the first half of 2024 was 25,643.28 yuan, benefiting from a 50% reduction due to pollutant concentrations being below 50% of the standard limits[70] - The company's wastewater discharge permit allows a daily discharge volume of 400m³, with pollutants meeting the GB/T31962-2015 standard[71] - The company's environmental credit rating for 2024 is classified as "Green Label" according to the Shandong Province Enterprise Environmental Credit Evaluation[71] - The company has successfully passed ISO14001 and ISO45001 system audits, emphasizing energy conservation, pollution prevention, and safety[69] - The company has implemented an environmental emergency response plan, including regular drills and detailed environmental risk management measures[69] - The company's wastewater discharge at the main plant site includes COD at 28.8mg/L, ammonia nitrogen at 2.09mg/L, and total nitrogen at 25.7mg/L, all within permitted limits[66] - The company's volatile organic compound emissions are at 29.45mg/m³, well below the permitted limit of 15.734 tons[66] - The company has no record of environmental penalties during the reporting period, indicating compliance with environmental regulations[71] - The company's environmental credit rating for 2024 is Green Label, indicating compliance with environmental standards[72] Corporate Governance and Compliance - The company's financial reports are signed by the legal representative, financial officer, and accounting officer, ensuring accuracy and completeness[3] - The company's financial reports and disclosed documents are available at the company's securities department[3] - The company has no significant legal disputes, penalties, or bankruptcy-related issues during the reporting period[74][75][76] - No non-operational fund occupation by controlling shareholders or related parties was reported[74] - The company provided guarantees totaling 90,000 million yuan for subsidiaries, with actual guarantees issued amounting to 7,419 million yuan[83] - The total actual guarantee balance for subsidiaries at the end of the reporting period was 9,789 million yuan, accounting for 2.56% of the company's net assets[83] - The company engaged in bank wealth management products with a total investment of 31,329.5 million yuan, of which 10,900 million yuan remains outstanding[84] - No significant related-party

证券代码：002675 证券简称：东诚药业 公告编号：2024-050 2024 年 8 月 2 日，烟台东诚药业集团股份有限公司（以下简称"公司"）控 股子公司烟台蓝纳成生物技术有限公司（以下简称"蓝纳成"）收到中国国家药 品监督管理局（以下简称"国家药监局"）核准签发的关于 177Lu-LNC1011 注射 液的药品临床试验批准通知书，将于近期开展临床试验。 | | | | 药物名称 | 177Lu-LNC1011 注射液 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | 号 IND | CXHL2400545 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查， | | | 你公司提交的 177Lu-LNC1011 注射液临床试验申请符合 | | | 药品注册的有关要求，同意本品开展前列腺癌的临床试验。 | 一、药物的基本情况 烟台东诚药业集团股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 二、药物的其他情况 1、公司在研产品 ...

如下： 证券代码：002675 证券简称：东诚药业 公告编号：2024-049 烟台东诚药业集团股份有限公司 关于实际控制人部分股权解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"或"本公司"）于2024 年7月18日收到公司实际控制人由守谊先生的通知，由守谊先生将其持有的本公 司部分股权进行解除质押，具体情况如下： 根据《通知》所述，截至2024年7月18日由守谊先生持有东诚药业股票 103,305,678股，累计质押46,630,000股，累计质押股份占所持股份总数的45.14%， 股权质押风险总体可控，目前不存在平仓风险。 二、股东所持股份累计被质押的情况 截至公告披露日，实际控制人由守谊先生及其一致行动人所持质押股份情况 1、中国证券登记结算有限责任公司股份冻结明细 2、交易对账单 特此公告。 烟台东诚药业集团股份有限公司董事会 | | | | | | 占公 | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | - ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-039 烟台东诚药业集团股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 4 月 26 日，烟台东诚药业集团股份有限公司（以下简称"公司"或 "上市公司"）控股子公司烟台蓝纳成生物技术有限公司（以下简称"蓝纳成"） 收到中国国家药品监督管理局（以下简称"国家药监局"）核准签发的关于 177Lu- LNC1008 注射液的药物临床试验批准通知书，将于近期开展临床试验。 现将 177Lu-LNC1008 注射液相关情况公告如下： | 药物名称 | 177Lu-LNC1008 注射液 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | 受理号 | CXHL2400195 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查， | | | 你公司提交的 177Lu-LNC1008 注射液临床试验申请符合药 | | | 品注册的有关要求，同意本品开展晚期实体瘤的临床试验。 ...

Financial Performance - The company's operating revenue for 2023 was ¥3,275,647,886, a decrease of 8.58% compared to ¥3,582,955,420 in 2022[18]. - Net profit attributable to shareholders for 2023 was ¥209,735,777, down 31.75% from ¥307,289,459 in 2022[18]. - The net profit after deducting non-recurring gains and losses was ¥212,479,028, a decrease of 26.17% from ¥287,799,050 in 2022[18]. - The net cash flow from operating activities was ¥276,944,524, a significant decline of 72.21% compared to ¥996,537,274 in 2022[18]. - Basic earnings per share for 2023 were ¥0.2543, down 33.15% from ¥0.3804 in 2022[18]. - The weighted average return on net assets was 4.53%, a decrease from 6.79% in 2022[18]. - Total assets at the end of 2023 were CNY 8,082,354,400, a decrease of 1.16% compared to the end of 2022[19]. - Net assets attributable to shareholders at the end of 2023 were CNY 4,775,401,460, an increase of 0.56% from the end of 2022[19]. - The company reported a total of CNY 24,958,065.56 in government subsidies for 2023, slightly up from CNY 24,123,274.18 in 2022[25]. - The company achieved a net profit attributable to shareholders of RMB 209,735,777.71 for the year 2023, with a profit distribution plan that includes a cash dividend of RMB 1.25 per 10 shares, totaling RMB 103,074,463.13[165]. Risk Management - The company emphasizes the importance of risk awareness regarding potential risks such as raw material procurement, product quality, and price fluctuations[3]. - Future development statements in the report are considered forward-looking and do not constitute a commitment to investors, urging caution regarding investment risks[3]. - The company faces risks related to raw material procurement and price fluctuations, particularly for heparin sodium, due to a significant decrease in pig inventory caused by African swine fever, which has led to a sharp increase in raw material prices[120]. - Increased depreciation from high fixed asset investments may lead to a decline in performance, especially if new projects generate insufficient revenue to cover initial depreciation costs[121]. - The company is exposed to risks from strict environmental regulations, which may increase expenditures on pollution control and compliance as societal awareness of environmental issues grows[122]. - There is a risk that pharmaceutical research and development may not meet expectations, as the lengthy approval process and high entry barriers can delay product launches and increase costs[121]. - The company may face management risks due to rapid expansion and acquisitions, which could complicate organizational structure and operational efficiency[121]. - The company is subject to risks from ongoing pharmaceutical reforms, including stricter drug approval and pricing policies that could impact future growth[121]. - Currency exchange rate fluctuations pose a risk to the company's revenue from exports and dollar-denominated borrowings, potentially affecting overall financial performance[122]. Research and Development - The company is focused on research and development in new products and technologies, although specific details are not provided in the extracted content[10]. - The company continues to focus on the development of radiopharmaceuticals and related technologies[12]. - R&D investment reached CNY 313.14 million, a year-on-year increase of 77.23%, with 76.73% allocated to radiopharmaceutical development[66]. - The company is actively expanding its product pipeline with multiple clinical trials in progress, indicating a strong focus on innovation and market growth[82]. - The company has launched 7 positron emission drug production centers and plans to exceed 30 centers, covering 93.5% of the domestic nuclear medicine demand[53]. - The company has established an integrated innovation platform for radiopharmaceuticals, focusing on multiple cancers, with ongoing clinical trials for several products, including [18F] fluoropetide injection in Phase III trials[49]. - The company is focused on developing innovative drugs for malignant tumors, neurodegenerative diseases, and cardiovascular conditions, with a strong emphasis on R&D investment[58]. - The company plans to continue expanding its product pipeline and R&D efforts, focusing on oncology and neurodegenerative diseases[66]. Governance and Compliance - The company maintains a strong governance structure, ensuring compliance with legal regulations and protecting shareholder rights[127]. - The board of directors includes independent members, ensuring a balanced governance approach and adherence to regulatory requirements[128]. - The company has established a complete internal audit system with a dedicated department of seven professionals, ensuring effective internal supervision of daily operations[131]. - The company maintains independence from its controlling shareholders in terms of business operations, personnel, assets, organization, and finance, with no significant related party transactions affecting independence[134]. - The company has a dedicated investor relations management team, ensuring equal access to information for all shareholders through multiple communication channels[132]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication of relevant information to investors[130]. - The company has established a robust internal control system, with no major defects identified in the internal control evaluation report[171]. - The company has implemented a change in accounting policy effective January 1, 2023, in accordance with the Ministry of Finance's announcement regarding deferred income tax related to individual transactions[196]. Market Presence and Strategy - The company is committed to expanding its market presence and enhancing its product offerings[12]. - The company has established stable supply relationships with numerous large and medium-sized hospitals across the country, enhancing its market presence in the nuclear medicine sector[42]. - The company aims to enhance its academic support for healthcare professionals through specialized marketing teams and participation in professional conferences, thereby increasing its influence in the anticoagulation field[44]. - The company is exploring opportunities in the international market for its medical devices and pharmaceuticals, with a focus on regulatory compliance[101]. - The company plans to expand its market presence through strategic partnerships and acquisitions, including the acquisition of Kenne LLC[100]. - The company aims to maintain existing market share while actively exploring new customers and markets to enhance sales coordination[119]. - The company plans to distribute profits through cash dividends, stock dividends, or other legally permitted methods, prioritizing cash dividends when conditions allow[193]. Environmental Responsibility - Yantai Dongcheng Pharmaceutical Group reported a wastewater discharge of 2.08 tons and a total nitrogen discharge of 1.33 tons, both compliant with the GB/T31962-2015 standard[176]. - The company has a valid pollution discharge permit from August 1, 2020, to August 1, 2025[176]. - The wastewater treatment facilities utilize a combination of hydrolysis, anaerobic, and aerobic processes, ensuring stable discharge concentrations[178]. - The company has implemented real-time monitoring of pollutant discharge at wastewater outlets[178]. - The company has established an annual environmental monitoring plan, combining external and self-monitoring methods[179]. - Emergency response plans for environmental incidents have been developed and regularly rehearsed to enhance safety management[180]. - The company continues to optimize laboratory waste gas treatment to comply with environmental regulations[181]. - The company has completed the reapplication for its pollutant discharge permit, ensuring compliance with environmental standards[183]. Employee Management - The total number of employees at the end of the reporting period was 2,333, including 427 at the parent company and 1,906 at major subsidiaries[158]. - The company emphasizes a fair and competitive salary system to attract and retain talent, with management salaries linked to performance and market conditions[159][160]. - The company is focused on employee training and development, implementing various training programs to enhance knowledge, skills, and management capabilities[161][162]. - The company has a total of 63 retired employees for whom it bears costs[158]. - The company’s management salary system aims to align with market standards and ensure motivation among employees[160]. Strategic Initiatives - The company has achieved a significant increase in capitalized R&D expenditures, which rose by 780.52% to ¥115,915,200.43 in 2023[82]. - The company is considering potential mergers and acquisitions to bolster its market position and diversify its product range[147]. - The company has established a comprehensive performance evaluation system for senior management, linking their compensation directly to work performance and company operating results[148]. - The company is actively involved in various subsidiaries and joint ventures, enhancing its market presence and operational capabilities[147].

证券代码：002675 证券简称：东诚药业 公告编号：2024-038 烟台东诚药业集团股份有限公司 关于举行 2023 年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）定于 2024 年 5 月 8 日 （星期三）15：00—17:00 举行 2023 年度网上业绩说明会。本次业绩说明会将 采用网络远程的方式举行，投资者可通过"价值在线"（http://www.ir-online.cn） 平台参与本次业绩说明会。 出席本次年度业绩说明会的人员有：公司总经理罗志刚先生、财务负责人朱 春萍女士、独立董事赵大勇先生、董事会秘书刘晓杰先生。（如有特殊情况，参 与人员会有调整。） 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度网上业绩说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 5 月 7 日（星期二）17：00 前使用微信扫描下方小程序码进行会前提问，进 入问题征集专题页面。公司将在 2023 年度网上业绩说明会上，对投资者普遍关 注 ...

烟台东诚药业集团股份有限公司 表决结果：同意2票，反对0票，弃权0票。 第六届董事会第一次独立董事专门会议 独立董事：李方、赵大勇 一、董事会会议召开情况 2024 年 4 月 26 日 2024 年 4 月 26 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 召开了第六届董事会第一次独立董事专门会议。会议通知于 2024 年 4 月 16 日以 通讯方式送达，会议应出席独立董事 2 人，实际出席独立董事 2 人，会议的召集、 召开和表决程序符合《公司章程》、《上市公司独立董事管理办法》、《独立董事工 作制度》等规定。 二、会议审议情况 全体独立董事经过审议，审议通过了如下议案： 一、《关于确认 2023 年度日常关联交易的议案》 经审核，我们认为：公司预计的 2023 年日常关联交易金额是根据双方可能 发生业务进行的评估和测算，实际发生额是按照双方实际签订合同金额和执行进 度确定，具有较大的不确定性。公司与新旭生技前期委托的 CRO 公司达成了良 好合作，后续临床服务由公司与 CRO 公司间直接结算，导致关联交易发生额与 预期差异较大，不会影响公司的正常经营，也不会损害公司股东，尤其是中小股 东的利 ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-026 烟台东诚药业集团股份有限公司关于续聘 中天运会计师事务所（特殊普通合伙） 为公司 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 26 日，烟台东诚药业集团股份有限公司（以下简称"公司"或"本 公司"）在山东省烟台经济技术开发区长白山路 7 号公司会议室召开了第六届董事 会第四次会议。会议审议通过了《关于续聘中天运会计师事务所（特殊普通合伙） 为公司 2024 年度审计机构的议案》，鉴于中天运会计师事务所（特殊普通合伙）（以 下简称"中天运"）具备证券、期货相关业务从业资格，具有多年上市公司审计工作 的丰富经验和职业素养，其在担任公司审计机构期间，勤勉尽责，坚持独立、客观、 公正的审计准则，公允合理地发表审计意见。为保证审计工作的连续性，公司拟续 聘中天运会计师事务所（特殊普通合伙）为公司 2024 年度审计机构，承办公司 2024 年度的审计等注册会计师法定业务及其他业务。现将相关事宜公告如下： 一、拟聘任会计师事务所的情况说明 （一） ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-030 根据中国证监会、深圳证券交易所有关法律、法规和规范性文件及《公司章 程》的有关规定，以上担保事项经董事会审议通过后，尚需提交2023年度股东大 会审议批准。 二、 担保额度预计明细表 单位：万元 烟台东诚药业集团股份有限公司 关于 2024 年度为子公司及其下属公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 担保情况概述 烟台东诚药业集团股份有限公司（以下简称"公司"或"东诚药业"）于2024年 4月26日召开第六届董事会第四次会议，审议通过了《关于2024年度为子公司及 其下属公司提供担保额度预计的议案》。 为满足公司经营发展需要，公司董事会同意公司对合并报表范围内的子公司 及其下属公司提供担保，预计2024年度上述担保额度合计不超过人民币9亿元（或 等值外币），额度内可循环滚动操作。授权公司及子公司法定代表人或其授权人 员根据实际经营需要，在前述额度内分别代表其所在公司签署相关文件。上述授 权有效期自2023年度股东大会审议批准之日起至2024年度股东 ...